Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease

Next Previous
X
Search
Trial Profile

Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium phenylbutyrate/ursodoxicoltaurine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEGASUS
  • Sponsors Amylyx Pharmaceuticals

    • Most Recent Events

    • 07 Nov 2024 According to an Amylyx Pharmaceuticals media release, data consisting exploratory analyses on CSF biomarkers from participants with AD from the Phase 2 PEGASUS clinical trial was published in the peer-reviewed medical journal Alzheimer & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer Association.
    • 26 Apr 2022 Safety and tolerability results from CENTAUR, CENTAUR-OLE and PEGASUS studies, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
    • 04 Apr 2022 According to an Amylyx Pharmaceuticals media release, data from the trial was presented at the 2022 American Academy of Neurology Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top